Under terms of the Agreement, Axella will contribute over $1m in funding and the delivery of key clinical research organization (CRO) services, including the management and execution of
RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. The open label Phase IIa study (the
The milestone stems from Sanofi’s decision to continue advancing the tetraspecific Anticalin-based program for infectious disease. The drug candidate selectively binds four classes of siderophores produced by Pseudomonas
The strategic move between Takeda, an R&D driven pharmaceutical company which has a long history as a leading company in Japan, and Teva, among the top ten pharmaceutical
The approval of this first and only immunostimulatory antibody for multiple myeloma is based on data from the randomized, open-label, Phase 3, ELOQUENT-2 study, which demonstrated that the
biOasis’ Transcend Platform was originally based on the protein known as melanotransferrin (MTf or p97). Researchers at biOasis hypothesized that smaller sequences within the 80 kDa protein would
Introduced at the 2015 Radiological Society of North America Annual Meeting (RSNA) in Chicago, IL , IntelliSpace Portal 8.0 helps address the changing demands in radiology that result
The world’s first Twin Robotic X-ray system, the Multitom Rax boasts a unique design that enables, for the first time, the acquisition of 3D natural weight-bearing images.¹ Siemens
The agreement was signed between Kuroiwa Yuji, Governor of the Kanagawa Prefecture, and Keith Thompson, the CEO of the Cell Therapy Catapult. The agreement involves a commitment for
The partnership aims to offer a strategic research platform for Fox Chase Cancer Center – Temple Health and Accutest Research Laboratories to conduct clinical trials in the United
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.